Compare SPRO & AIFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRO | AIFC |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 73.3M |
| IPO Year | 2017 | 1994 |
| Metric | SPRO | AIFC |
|---|---|---|
| Price | $1.21 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 607.0K | ★ 923.4K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,802,000.00 | $12,532,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.08 | $0.36 |
| 52 Week High | $3.08 | $0.72 |
| Indicator | SPRO | AIFC |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 60.64 |
| Support Level | $1.18 | $0.52 |
| Resistance Level | $1.29 | $0.63 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 16.00 | 63.10 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.